602 THE CANDIDATE HCV E1E2MF59 VACCINE IS SAFE IN CHRONIC HEPATITIS C PATIENTS AND ACCELLERATES THE SECOND PHASE VIRAL DECLINE UPON PRIMARY RESPONSE TO PEG-INTERFERON-2A/RIBAVIRIN THERAPY
P. Colombatto(Azienda Ospedaliera Universitaria Pisana), Ferruccio Bonino(Ospedale Santa Chiara), Vincenzo Barnaba(Istituto Pasteur), Giovambattista Pinzello(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), M. Sarracino, Sergio Abrignani(Istituto Nazionale Genetica Molecolare), A Muzzi(Policlinico San Matteo Fondazione), Silvia Montigiani, F. B. Bianchi, Maurizia Rossana Brunetto(University of Pisa), Silvia Fargion(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Rino Rappuoli(University of Siena), Mario U. Mondelli(University of Pavia), Maria Grazia Rumi(University of Milan), Michael Houghton(University of Alberta), Antonio Craxı̀(University of Palermo), Antonio Ascione(Ospedale Antonio Cardarelli), P.L. Almasio, V. Romagnoli(University of Pisa), A.M. Maina(University of Pisa), S. Madonia, Domenico Rosa(Novartis (Italy)), M. Colombo(University of Milan)
Cited by 1
Related Papers
<i>cag</i> , a pathogenicity island of <i>Helicobacter pylori,</i> encodes type I-specific and disease-associated virulence factors
|Proceedings of the National Academy of Sciences|1996|1.9k
Detection of Antibody to Hepatitis C Virus in Prospectively Followed Transfusion Recipients with Acute and Chronic Non-A, Non-B Hepatitis
|New England Journal of Medicine|1989|1.7k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
A proposed system for the nomenclature of hepatitis C viral genotypes
|Hepatology|1994|1k